On April 14th, Ernst & Young released the white paper "Zhiqi New Quality Productivity: Potential Application of Generative Artificial Intelligence in Medical and Pharmaceutical Fields" at the 4th China International Consumer Goods Expo. In response to the call of "accelerating the development of new quality productivity" put forward by the state, this white paper deeply thinks about the potential transformative power, fusion power, scene power and empowerment value of generative artificial intelligence in the medical and pharmaceutical field from the application level, and looks forward to the broad prospects brought by this emerging digital technology in combination with policy compliance requirements. At the same time, it points out that Hainan, the hot spot of "China practice" of new quality productivity, is promoting the digital development of medical and pharmaceutical industry with the policy process of "Hainan speed"
(Photo courtesy of Ernst & Young)
Wu Xiaoying, co-managing partner of Ernst & Young’s life science and medical and health industry in Greater China, said: "Generative artificial intelligence, as a hot spot in the field of science and technology, has broad application prospects in the medical and pharmaceutical fields. The emergence of this technology is not only expected to further improve the efficiency and quality of medical services, but also has the opportunity to help the innovation and development of the medical and pharmaceutical industry. We hope that through this white paper, we can provide people inside and outside the industry with a comprehensive scene prospect and understand the potential value of generative artificial intelligence in the medical and pharmaceutical field. At the same time, we also know that the progress of the industry cannot be separated from the guidance and regulation of policies. Therefore, in the process of promoting the digital application of the industry, Ernst & Young will also actively cooperate with government departments, industry partners and all walks of life to jointly promote the compliance, health and sustainable development of the medical and pharmaceutical industry with professional services. "
"Generative artificial intelligence is expected to further empower the medical and pharmaceutical industry in more fields on the basis of the previous generation of artificial intelligence, and provide more effective tools and solutions for the development of the industry. In the future, by combining with advanced technologies in other fields such as big data, cloud computing and Internet of Things, generative artificial intelligence will promote the innovative development of the medical and pharmaceutical industry and improve the accessibility and efficiency of medical services. " Wu Miao, consulting service director of Ernst & Young Greater China, said.
Transformational power: from traditional AI to generative AI, it is both evolution and rebirth.
The white paper points out the trend changes in the process of artificial intelligence innovation. On the one hand, the development of generative AI has made a leap from structured processing to specialized and interactive generation, which includes the different properties and different degrees of development of "change" and "revolution". "Change" represents the extension or progress of generative AI based on previous technology, while "leather" represents a leap forward in generative AI that is significantly different from previous technology. On the other hand, in the future, traditional AI and generative AI will continue to exert their combined efforts, coordinate and win-win together, which will enable AI technology to play a greater role in various fields. Whether it is medical or other industries, generative AI can provide better services for human beings and bring richer experiences.
(Photo by Chen Bowen)
Integration: Promote cross-border integration in medical and pharmaceutical fields and deeply influence patients’ journey.
The convergence of generative AI is leading the cross-border integration in medical and pharmaceutical fields, bringing changes to patients’ journey. In every link of the patient’s journey, the generative AI has shown a strong integration potential. Using big data, cloud computing and Internet of Things technologies, AI has realized intelligent management and remote monitoring of medical equipment, greatly improving the efficiency and accessibility of medical services. This reform not only improves the productivity of the industry, but also ensures that patients get timely and accurate treatment.
(Photo by Chen Bowen)
Empowering doctors and patients: Generative AI makes diagnosis and treatment "better in quality and efficiency" and makes patients "better in experience"
Generative AI can be applied to patients’ journey and play a role in many scenarios such as cognition, treatment, treatment and follow-up of diseases. Through the diverse scenes of doctors and patients from different perspectives, generative AI can make the diagnosis and treatment "better", the doctors "more professional" and the patients "more independent". On the one hand, new technology empowers hospitals and doctors, helping doctors to release more work efficiency, improve work quality and alleviate the problem of medical resources shortage. On the other hand, new technologies combined with patients’ journey bring more accurate, convenient and personalized medical services and health support, promote the in-depth development of patients’ self-knowledge and enhance innovative interactive experience.
Empowering the operation scenario of pharmaceutical companies: the long-term enhancement of "front-middle-back" core by generative AI
In all aspects of the operation of pharmaceutical companies, generative AI will play an increasingly important role, which will not only change the traditional drug research and development and production mode, but also provide strong support for the front, middle and back-office operations of pharmaceutical companies. Among the functional departments at the front desk, generative AI will mainly empower patients in the fields of patient service, marketing market analysis and enterprise strategic planning, improve the doctor-patient experience through intelligent consultation and precision marketing, and provide more accurate business planning and operation optimization for pharmaceutical companies. In the middle and back office departments of enterprises, the core applications of generative AI will include drug research and development, production and supply chain optimization, which will play a role in accelerating the listing process of new drugs and reducing costs and increasing efficiency. In addition, generative AI can help production automation, quality control and IT operation and maintenance, improve production efficiency and ensure stable operation.
Challenges and countermeasures under the policy: based on "number", follow the rules
With the rapid development of artificial intelligence in China, government supervision keeps pace with the times. A number of laws and regulations, represented by the Interim Measures for the Management of Generative Artificial Intelligence Services, have been adopted to supervise generative AI. In recent years, under the background of medical anti-corruption storm, multi-link supervision has been upgraded and industry policies have been updated frequently. Therefore, relevant enterprises need to follow up in time, master relevant policies such as artificial intelligence, data governance and network security, and combine the characteristics of medical and pharmaceutical fields to prevent, identify and avoid risks in advance.
Unity of knowing and doing: Hainan practice of China’s new quality productivity
The relevant person in charge of Ernst & Young pointed out that at present, Hainan is accelerating the development of international medical tourism and high-end medical services to attract the return of international medical consumption. Here, we not only witnessed the implementation of a series of innovative policies such as digital therapy and drug trial first, but also saw the innovative methods such as "investing in Qionghai enterprise through train". Through this series of measures, Hainan is gradually building a new quality productivity system with local characteristics, injecting new impetus into the high-quality development of China’s economy.
(China Daily Hainan reporter station Chen Bowen)
Source: China Daily.
Reporting/feedback